PAVmed Inc , a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc, announced that the Veris Cancer Care Platform CCP, designed to enhance personalized cancer care through remote patient monitoring (RPM), is now live following successful onboarding of the first cohort of cancer patients and their clinicians.
Enrolled patients received a VerisBox and were then successfully trained to use its Veris-branded Bluetooth-enabled connected health care devices to transmit real-time physiologic data to the cloud-based Veris CCP clinician portal via an embedded cellular connection. The patients also began reporting symptoms, as well as general health and quality of life parameters, to their cancer care team through the Veris CCP patient smartphone app . The app is now available on the Apple App Store and Google Play. The cloud-based clinician portal was integrated into the oncology practice’s information technology systems and the cancer care team was trained to use the portal to review physiologic and clinical data to deliver enhanced personalized care, allowing the practice to start billing for these RPM services on a monthly basis.
“We are very excited that the promise of enhancing personalized cancer care through RPM using our state-of-the-art digital health platform, Veris CCP, has become a reality for cancer patients and their clinicians,” said Lishan Aklog, M.D., PAVmed’s Chairman & Chief Executive Officer and Veris’ Executive Chairman. “Our team together with the New Jersey Cancer Care team flawlessly executed the required technical integration and onboarding processes. Early reports of our platform already having a real impact on clinical care are very gratifying. Our software-as-a-service recurring-revenue business model is now poised to deliver near-term value at attractive margins to both Veris and its clients.”
“With the platform now live and facilitating enhanced cancer care, our focus is on optimizing the patient and clinician experience, achieving high patient compliance, and streamlining the integration processes as our commercial team drives adoption and delivers new accounts. We look forward to furthering the power of the platform next year, with the anticipated launch of our implantable physiological monitor,” Dr. Aklog added.
SOURCE: PR Newswire